Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cedars-Sinai Medical Center

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
664
Shown on this page
12
Current sort
Recently updated
Campus scope
Cedars-Sinai Medical Center, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cedars-Sinai Medical Center, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 577–588 of 664 matching trials with a site at Cedars-Sinai Medical Center, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand

NCT05747469
Site status not listed — check the official record
View directory record Official record
Conditions
Osteoarthritis Hand
Interventions
local anaesthetic injection, Human Adipose Allograft
Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 31, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

NCT06182397
Status at this site: Recruiting
View directory record Official record
Conditions
Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions
MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
21 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 31, 2026, 10:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

Family Foundations for Individuals Pregnant Via ART

NCT06770972
Status at this site: Recruiting
View directory record Official record
Conditions
Assisted Reproductive Technology
Interventions
Family Foundations
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

NCT07299474
Status at this site: Recruiting
View directory record Official record
Conditions
Inferior Turbinate Hypertrophy, Chronic Rhinosinusitis (CRS), Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Active, not recruiting Phase 3 Interventional

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992
Site status not listed — check the official record
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

NCT04889872
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Stenosis, Calcific, Aortic Valve Stenosis
Interventions
SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
65 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2037
U.S. locations
65
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Recruiting Phase 2 Interventional

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
446
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer

NCT06856694
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer, Shared Decision Making, Risk Communication
Interventions
NLP+AI Report
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986
Site status not listed — check the official record
View directory record Official record
Conditions
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions
Olaparib 300mg tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
81
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 31, 2026, 10:29 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT04625647
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Sotorasib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
828
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 561 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 31, 2026, 10:29 AM EDT

About this Cedars-Sinai Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Cedars-Sinai Medical Center in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.